Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Tonix Pharmaceuticals Holding Corp (TNXP)

10.03 Up 0.06(0.60%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Tonix Pharmaceuticals Holding Corp
509 Madison Avenue
Suite 306
New York, NY 10022
United States - Map
Phone: 212-980-9155
Fax: 212-923-5700

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:6

Business Summary 

Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company’s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Tonix Pharmaceuticals Holding Corp

Key Executives 
Dr. Seth Lederman M.D., 56
Co-Founder, Chairman, Chief Exec. Officer and Pres
Dr. Donald W. Landry M.D., Ph.D., 59
Co-Founder, Director and Member of Governance & Nominating Committee
Dr. Leland Gershell M.D., Ph.D., 42
Chief Financial Officer, Principal Accounting Officer and Treasurer
Dr. Bruce L. Daugherty Ph.D., M.B.A., 56
Sr. Director of Drug Devel., Controller and Sec.
Dr. Donald J. Kellerman Pharm.D., 59
Sr. VP of Clinical Devel. and Regulatory Affairs
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders